Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYALOSET 2000 is a medical device developed by RiverPharma, designed as a synovial fluid substitute for patients suffering from degenerative or mechanical arthropathy. The product is a sterile, apyrogenic, viscoelastic solution containing 1.5% high molecular weight sodium hyaluronate (>2000 kDa) produced via bacterial fermentation. It is administered through intra-articular injection to restore the natural rheological properties of synovial fluid, which are often compromised in traumatic or degenerative joint diseases. By improving joint lubrication and shock absorption—a process known as viscosupplementation—SYALOSET 2000 helps reduce pain and restore mobility without interacting with specific biological receptors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SYALOSET 2000.